Identification of β4GALNT2 as an anti-hPIV3 factor through genome-wide CRISPR/Cas9 library screening

Publication date

2025-12

Authors

Wu, Xuesheng
Luteijn, Rutger D.ISNI 0000000419536104
Lozano-Andrés, Estefanía
Marougka, Katherine
Li, W.
Narimatsu, Yoshiki
van Kuppeveld, Frank J M
Bosch, Berend Jan
Lebbink, Robert JanORCID 0000-0002-1981-0420ISNI 0000000393301103
Vries, Erik de

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Human respirovirus 3 (also known as human parainfluenza virus 3; hPIV3) is a major cause of severe acute respiratory infections in vulnerable populations. Here we conducted a genome-wide CRISPR/Cas9 library screen to identify key host factors for hPIV3 infection. In addition to identifying several host proteins involved in glycosylation as proviral factors, we identified β-1,4-N-Acetyl-Galactosaminyltransferase 2 (β4GALNT2) as a potent restriction factor. Further investigation demonstrated that the addition of a GalNAc residue to α2-3-sialylated glycans by β4GALNT2, resulting in the Sda glycotope, disrupted the interaction between the viral hemagglutinin-neuraminidase (HN) attachment protein and sialoglycan receptors. Specifically, the additional GalNAc residue interfered with the interaction of residue W371 in HN with sub-terminal glycan moieties. β4GALNT2-mediated Sda epitope expression also negatively affected infection by other respiroviruses, with the strongest effect being observed for hPIV3.

Keywords

Animals, CRISPR-Cas Systems, Glycosylation, HEK293 Cells, Host-Pathogen Interactions, Humans, N-Acetylgalactosaminyltransferases/genetics, Parainfluenza Virus 3, Human/physiology, Polypeptide N-acetylgalactosaminyltransferase, Polysaccharides/metabolism, Respirovirus Infections/virology, Journal Article

Citation

Wu, X, Luteijn, R D, Lozano-Andrés, E, Marougka, K, Li, W, Narimatsu, Y, van Kuppeveld, F J M, Bosch, B J, Lebbink, R J, Vries, E D & de Haan, C A M 2025, 'Identification of β4GALNT2 as an anti-hPIV3 factor through genome-wide CRISPR/Cas9 library screening', Emerging microbes & infections, vol. 14, no. 1, 2529895. https://doi.org/10.1080/22221751.2025.2529895